Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus placebo
neratinib
ExteNET, 2016
  NCT00878709
RCTbreast cancer - adjuvant, la/mBC - HER2 positive - 2nd Line (L2)neratinibplaceboWomen with locally confirmed invasive HER2-positive BC stage 1-3, who had received trastuzumab and chemotherapy.1420 / 1420low
conclusif
  • demonstrated 33 % decrease in iDFS (PE)
  • suggested 37 % decrease in RFS/DFS